Ishares Trust · net assets $8.12B · 258 holdings as of March 31, 2026. Monthly N-PORT disclosure: the full book, not just equities.
EC: 91.0% · STIV: 9.0% · OTHER: 0.0% · DE: 0.0%
| Month 1 | Month 2 | Month 3 | |
|---|---|---|---|
| Sales | $829M | $1.21B | $942M |
| Reinvestment | $0 | $0 | $0 |
| Redemptions | $808M | $1.11B | $1.27B |
| Net realized gain (non-derivative) | $135M | $196M | $133M |
| Net unrealized appreciation (non-derivative) | $41.7M | $-52M | $-457M |
The three months of the reporting period, as filed; month 3 ends March 31, 2026.
| Holding | Value | % of net assets |
|---|---|---|
| Blackrock Funds Iii STIV | $785M | 9.66% |
| Gilead Sciences, Inc. EC | $629M | 7.75% |
| Amgen, Inc. EC | $610M | 7.51% |
| Vertex Pharmaceuticals, Inc. EC | $605M | 7.44% |
| Regeneron Pharmaceuticals, Inc. EC | $586M | 7.21% |
| Alnylam Pharmaceuticals, Inc. EC | $324M | 3.99% |
| Insmed, Inc. EC | $260M | 3.20% |
| Argenx Se EC | $250M | 3.07% |
| Biogen, Inc. EC | $200M | 2.46% |
| Natera, Inc. EC | $196M | 2.41% |
| United Therapeutics Corp. EC | $187M | 2.30% |
| Beone Medicines Ltd. EC | $157M | 1.93% |
| Incyte Corp. EC | $138M | 1.70% |
| Moderna, Inc. EC | $137M | 1.68% |
| Illumina, Inc. EC | $136M | 1.68% |
| Revolution Medicines, Inc. EC | $125M | 1.54% |
| Roivant Sciences Ltd. EC | $101M | 1.24% |
| Neurocrine Biosciences, Inc. EC | $95.8M | 1.18% |
| Genmab A/s EC | $95.4M | 1.17% |
| Bridgebio Pharma, Inc. EC | $92M | 1.13% |
| Ionis Pharmaceuticals, Inc. EC | $90.5M | 1.11% |
| Medpace Holdings, Inc. EC | $81.6M | 1.00% |
| Madrigal Pharmaceuticals, Inc. EC | $81.3M | 1.00% |
| Exelixis, Inc. EC | $80.3M | 0.99% |
| Biomarin Pharmaceutical, Inc. EC | $79.8M | 0.98% |
| Ascendis Pharma A/s EC | $77.8M | 0.96% |
| Praxis Precision Medicines, Inc. EC | $62.9M | 0.77% |
| Charles River Laboratories International, Inc. EC | $62.5M | 0.77% |
| Arrowhead Pharmaceuticals, Inc. EC | $61.1M | 0.75% |
| Vaxcyte, Inc. EC | $60.8M | 0.75% |
| Bio-techne Corp. EC | $60.2M | 0.74% |
| Cytokinetics, Inc. EC | $59.1M | 0.73% |
| Halozyme Therapeutics, Inc. EC | $56.1M | 0.69% |
| Axsome Therapeutics, Inc. EC | $53.9M | 0.66% |
| Biontech Se EC | $53.3M | 0.66% |
| Krystal Biotech, Inc. EC | $48.8M | 0.60% |
| Protagonist Therapeutics, Inc. EC | $47.1M | 0.58% |
| Repligen Corp. EC | $46.8M | 0.58% |
| Kymera Therapeutics, Inc. EC | $43.4M | 0.53% |
| Alkermes PLC EC | $43M | 0.53% |
| Rhythm Pharmaceuticals, Inc. EC | $41.3M | 0.51% |
| Abivax Sa EC | $40.9M | 0.50% |
| Ptc Therapeutics, Inc. EC | $40.4M | 0.50% |
| Cogent Biosciences, Inc. EC | $38.9M | 0.48% |
| Arcellx, Inc. EC | $38.6M | 0.47% |
| Terns Pharmaceuticals, Inc. EC | $37.6M | 0.46% |
| Nuvalent, Inc. EC | $36.4M | 0.45% |
| Mirum Pharmaceuticals, Inc. EC | $36.3M | 0.45% |
| Tempus Ai, Inc. EC | $35M | 0.43% |
| Xenon Pharmaceuticals, Inc. EC | $34.8M | 0.43% |
| Amicus Therapeutics, Inc. EC | $33.4M | 0.41% |
| Crispr Therapeutics Ag EC | $31.6M | 0.39% |
| Apellis Pharmaceuticals, Inc. EC | $31.3M | 0.39% |
| Apogee Therapeutics, Inc. EC | $29.8M | 0.37% |
| Scholar Rock Holding Corp. EC | $29.2M | 0.36% |
| Acadia Pharmaceuticals, Inc. EC | $27.9M | 0.34% |
| Bruker Corp. EC | $27.6M | 0.34% |
| Crinetics Pharmaceuticals, Inc. EC | $26.4M | 0.32% |
| Cg Oncology, Inc. EC | $25.7M | 0.32% |
| Spyre Therapeutics, Inc. EC | $24.2M | 0.30% |
Showing top 60 of 258 holdings.
Loading...
